Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder
Status:
Withdrawn
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
In this study we hope to establish the prevalence of urinary urge symptoms (with or without
incontinence) in a multicultural, underserved, hospital clinic population in women between
the ages of 20 and 45. Quality of life (QOL) in these individuals will be examined. The goal
is to show a 15% reduction in number of voids in a 24 hour period in our study population
after 12 weeks of treatment with solifenacin succinate.
Hypothesis: We believe that urinary urge symptoms are under-reported in young women and
believe they pose a significant strain on quality of life on otherwise young, healthy
individuals. Treatment with solifenacin succinate will improve symptoms, in turn improving
QOL for these individuals.